Tocilizumab in Post Hematopoietic Stem Cell Transplant COVID-19: A Pediatric Case Report
Hematopoietic stem cell transplantation (HSCT) severely undermines the recipients' immune status and makes them prone to complications following viral infection. Here, we report a 3-year-old boy with mucopolysaccharidosis type VI who acquired SARS-CoV-2 infection after HSCT. The boy was dia...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pasteur Institute of Iran
2021-12-01
|
| Series: | Journal of Medical Microbiology and Infectious Diseases |
| Subjects: | |
| Online Access: | https://jommid.pasteur.ac.ir/article-1-388-en.html |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Hematopoietic stem cell transplantation (HSCT) severely undermines the
recipients' immune status and makes them prone to complications following
viral infection. Here, we report a 3-year-old boy with mucopolysaccharidosis
type VI who acquired SARS-CoV-2 infection after HSCT. The boy was
diagnosed with SARS-CoV-2 during the post-transplant period (19 days after
HSCT) when dealing with acute graft versus host disease (GVHD). He was
successfully treated with remdesivir and tocilizumab and recovered. Well-timed
treatment with tocilizumab might reduce the risk of invasive mechanical
ventilation and death in patients with severe COVID-19 pneumonia in the early
post HSCT period. |
|---|---|
| ISSN: | 2345-5349 2345-5330 |